Prices are updated after-hours

diabetes

Sino Biopharmaceutical Limited/ADR

SBMFF | $0.3624 64.18% 45K

(0.0% 1d) (0.0% 1m) (-33.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (19324.79% volume)
Earnings Calendar:
Market Cap: $ 6,813,561,124
http://www.sinobiopharm.com
Sec Filling | Patents | n/a employees

(HK) Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.

respiratory diabetic diabetes

add to watch list Paper trade email alert is off

Astellas Pharma Inc

ALPMF | $9.17 43.47% 16K

Health Technology

(0.0% 1d) (-11.6% 1m) (-35.8% 1y) (0.0% 2d) (0.0% 3d) (1.6% 7d) (-90.77% volume)
Earnings Calendar:
Market Cap: $ 16,594,610,398
http://www.astellas.com
Sec Filling | Patents | n/a employees

(JP) Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

brands infectious disease metabolic diabetic diabetes

add to watch list Paper trade email alert is off

ConvaTec Group PLC/ADR

CNVVF | $3.685 -18.0% 6.4K

Health Technology

(0.0% 1d) (-3.0% 1m) (31.6% 1y) (0.0% 2d) (0.0% 3d) (-5.0% 7d) (2130.18% volume)
Earnings Calendar:
Market Cap: $ 7,553,474,525
http://www.convatec.com
Sec Filling | Patents | n/a employees

(GB) ConvaTec Group Plc operates as holding company, which engages in medical business. Its activities include development, manufacture and sales of medical products and technologies related to therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care and management, continence and critical care, and infusion devices used in the treatment of diabetes and other conditions. The company was incorporated in 1978 and is headquartered in Reading, the United Kingdom.

treatment diabetic diabetes

add to watch list Paper trade email alert is off

Terumo Corp

TRUMF | $16.928 -17.59% 1.9K

Health Technology

(0.0% 1d) (-54.8% 1m) (-43.9% 1y) (0.0% 2d) (-2.2% 3d) (1.4% 7d) (-8.36% volume)
Earnings Calendar:
Market Cap: $ 25,234,523,556
http://www.terumo.co.jp
Sec Filling | Patents | n/a employees

(JP) Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan.

treatment diabetic diabetes communication pathogens ycombinator

add to watch list Paper trade email alert is off

SERNOVA CORP.

SEOVF | $0.3295 15.67% 29K

Health Technology

(0.0% 1d) (-19.4% 1m) (-45.9% 1y) (0.0% 2d) (0.0% 3d) (-3.0% 7d) (225.0% volume)
Earnings Calendar:
Market Cap: $ 99,972,833
http://www.sernova.com
Sec Filling | Patents | n/a employees

(CA) Sernova Corp. is a clinical stage regenerative medicine company. It engages in the business of developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins and hormones missing within the body. The firm also focuses in the manufacture and clinical evaluation of the cell pouch for insulin-dependent diabetes. The company was founded in 1992 and is headquartered in London, Canada.

metabolic hormone t-cell treatment diabetic diabetes ceiling insulin

add to watch list Paper trade email alert is off

Intellipharmaceutics International Inc.

IPCIF | $0.07 -29.49% 4.2K

Health Technology

(0.0% 1d) (-26.3% 1m) (9.1% 1y) (0.0% 2d) (0.0% 3d) (-55.6% 7d) (-37.58% volume)
Earnings Calendar:
Market Cap: $ 2,316,487
http://www.intellipharmaceutics.com
Sec Filling | Patents | n/a employees

(CA) Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of pharmaceuticals in the areas of neurology, cardiovascular, gastrointestinal tract, diabetes and pain. The company was founded by Isa Odidi and Amina Odidi in 1998 and is headquartered in Toronto, Canada.

gastrointestinal urea diabetic diabetes cardiovascular

add to watch list Paper trade email alert is off

Relief Therapeutics Holding SA

RLFTF | $1.43 11.45% 3.8K

n/a

(0.0% 1d) (-1.0% 1m) (7531.6% 1y) (0.0% 2d) (3.6% 3d) (9.8% 7d) (-56.37% volume)
Earnings Calendar:
Market Cap: $ 20,078,397
http://www.relieftherapeutics.com
Sec Filling | Patents | n/a employees

(CH) RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. It engages in the development and licensing of its portfolio of medicinal products candidates. Its products include aviptadil, for respiratory indications such as sarcoidosis and pulmonary hypertension; and atexakin alfa, for the treatment of diabetic neuropathy. The company was founded in June 2016 and is headquartered in Geneva, Switzerland.

treatment respiratory diabetes diabetic

add to watch list Paper trade email alert is off

GlucoTrack Inc

GCTK | $0.8191 22.25% 18.2% 190K

Manufacturing

(0.0% 1d) (145.0% 1m) (17.1% 1y) (0.0% 2d) (15.5% 3d) (82.2% 7d) (-70.31% volume)
Earnings Calendar:
Market Cap: $ 21,916,142
https://www.integrity-app.com
Sec Filling | Patents | 11 employees

(IL) Integrity Applications, Inc. was founded in 2001 and is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The Company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel.

diabetes diabetic

add to watch list Paper trade email alert is off

Humacyte Inc

HUMA | $3.7 3.06% 2.97% 4.9M

Manufacturing

(0.0% 1d) (2.8% 1m) (11.8% 1y) (3.1% 2d) (18.6% 3d) (28.9% 7d) (-15.47% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 440,609,794
https://humacyte.com
Sec Filling | Patents | n/a employees

Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

diabetic diabetes ceiling treatment defense t-cell

add to watch list Paper trade email alert is off

NOVO NORDISK A S

NONOF | $122.806 0.31% 5.1K

Health Technology

(0.0% 1d) (-5.4% 1m) (-29.0% 1y) (0.0% 2d) (-1.3% 3d) (-1.2% 7d) (-78.31% volume)
Earnings Calendar:
Market Cap: $ 421,661,962,043
http://www.novonordisk.com
Sec Filling | Patents | n/a employees

(DK) Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

hormone diabetic diabetes insulin

add to watch list Paper trade email alert is off

SAB Biotherapeutics Inc

SABS | $4.46 0.22% 890

(0.0% 1d) (-8.5% 1m) (443.0% 1y) (0.0% 2d) (-6.7% 3d) (-6.9% 7d) (-75.55% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 41,145,703
https://www.sabbiotherapeutics.com
Sec Filling | Patents | 5 employees

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB’s versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.

genetic cancer diabetes diabetic influenza covid

add to watch list Paper trade email alert is off

XORTX Therapeutics Inc.

XRTX | $3.5 -3.05% -3.14% 12K

Mining, Quarrying, and Oil and ...

(0.0% 1d) (-20.0% 1m) (429.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 6,995,968
http://www.xortx.com
Sec Filling | Patents | n/a employees

(CA) XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. XORTX Therapeutics is dedicated to developing medications to improve the quality of life and future health of patients.

injection kidney diabetes diabetic metabolic covid

add to watch list Paper trade email alert is off

Sigilon Therapeutics Inc

SGTX | $22.47 -2.56% 0.0% 0

Health Technology

(0.0% 1d) (0.0% 1m) (152.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (32.61% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 56,500,770
https://sigilon.com
Sec Filling | Patents | 2021 employees

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

diabetic diabetes ceiling t-cell

add to watch list Paper trade email alert is off

Intelligent Bio Solutions Inc

INBS | $2.71 -3.21% -3.32% 58K

Manufacturing

(0.0% 1d) (-25.3% 1m) (-11.3% 1y) (-2.1% 2d) (2.2% 3d) (-16.0% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 7,707,928
https://gbs.inc
Sec Filling | Patents | 8 employees

(US) GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes.

diagnostics diabetes diabetic covid

add to watch list Paper trade email alert is off

PharmaCyte Biotech Inc

PMCB | $2.2 0.0% 11K

Manufacturing

(0.0% 1d) (-12.0% 1m) (-28.9% 1y) (0.0% 2d) (0.0% 3d) (0.5% 7d) (20.64% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 18,597,471
https://www.pharmacytebiotech.com
Sec Filling | Patents | 4 employees

PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form.

diabetic diabetes msa ceiling cancer genetic t-cell

add to watch list Paper trade email alert is off

Sanofi

SNYNF | News | $92.7 -2.18% 600K

Health Technology

(0.0% 1d) (-2.7% 1m) (-16.9% 1y) (0.0% 2d) (0.0% 3d) (-0.3% 7d) (41938.42% volume)
Earnings Calendar:
Market Cap: $ 114,818,843,686
http://www.sanofi.com
Sec Filling | Patents | n/a employees

(FR) Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

vaccine diabetic diabetes cardiovascular

add to watch list Paper trade email alert is off

Aadi Biosciences Inc

AADI | $1.835 1.94% 1.91% 140K

Manufacturing

(0.0% 1d) (-14.4% 1m) (-76.9% 1y) (0.0% 2d) (0.0% 3d) (-3.2% 7d) (11.51% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 45,056,966
https://www.aerpio.com
Sec Filling | Patents | 12 employees

(US) Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase ("VE-PTP"). The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema ("DME"). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc.. In January 2021, the Company announced that it had initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources.

monoclonal antibodies antibody treatment diabetic diabetes injection macular

add to watch list Paper trade email alert is off

Tandem Diabetes Care, Inc.

TNDM | $30.445 -1.57% -1.59% 990K

Health Technology

(0.0% 1d) (-4.5% 1m) (-18.8% 1y) (0.0% 2d) (-4.2% 3d) (-4.5% 7d) (-6.4% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 1,965,635,027
http://www.tandemdiabetes.com
Sec Filling | Patents | 1043 employees

(US) Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

insulin diabetes diabetic msa

add to watch list Paper trade email alert is off

Biomerica, Inc.

BMRA | $0.7459 -1.86% -1.89% 35K

Health Technology

(0.0% 1d) (-27.0% 1m) (-57.8% 1y) (-3.9% 2d) (-3.9% 3d) (-5.2% 7d) (-36.03% volume)
Earnings Calendar: 2022-10-13
Market Cap: $ 12,547,266
http://www.biomerica.com
Sec Filling | Patents | 45 employees

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign. The company was founded in September 1971 and is headquartered in Irvine, CA.

gastrointestinal diabetes diabetic food diagnostics

add to watch list Paper trade email alert is off

Evoke Pharma, Inc.

EVOK | $0.493 2.97% 2.88% 1.9K

Health Technology

(0.0% 1d) (-20.3% 1m) (-75.8% 1y) (0.0% 2d) (0.0% 3d) (-1.1% 7d) (-92.36% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 4,179,556
http://www.evokepharma.com
Sec Filling | Patents | 5 employees

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

diabetes gastrointestinal diabetic women treatment